Cited by 360Cancer-related Molecular PathwaysCell death mechanisms and regulationGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Takimoto, R, El-Deiry, W S·2000·Oncogene

DOI 10.1038/sj.onc.1203489

Open this paper in CoChat — free account

Abstract

KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of its receptors is poorly understood. Here we show the identification of three p53 DNA-binding sites in the KILLER/DR5 genomic locus located upstream (BS1; -0.82 Kb) of the ATG site, within Intron 1 (BS2; +0.25 Kb downstream of the ATG) and within Intron 2 (BS3; +1.25 Kb downstream of the ATG). A modified p53-binding and immunoselection protocol using a wild-type p53-expressing adenovirus vector (Ad-p53) was used to identify the binding sites and to show that each binding site can bind specifically to wild-type p53 protein (wt-p53). A reporter assay revealed that only BS2 could enhance luciferase expression driven by a basal promoter. We constructed a reporter plasmid carrying the genomic regulatory region of KILLER/DR5 including the three p53 DNA-binding sites but no additional basal promoter. The genomic fragment showed basal transcriptional activity which was induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activation. Mutation of BS2 abrogated not only the binding activity of wt-p53 but also the induction of the KILLER/DR5 genomic promoter-reporter gene, indicating that BS2 is responsible for the p53-dependent transactivation of KILLER/ DR5. In p53-wild-type but not -mutant or -null cell lines, doxorubicin treatment stabilized p53 protein, and increased specific binding to BS2 as revealed by EMSA, and upregulated the KILLER/DR5 promoter-luciferase reporter gene. These results suggest that the transactivation of KILLER/DR5 is directly regulated by exogenous or endogenous wt-p53 and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1203489

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mitochondria and Apoptosis
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 9,051
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Self-citation
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Apoptosis by Death Factor
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,934
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Self-citation
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citation

Show all 39 references

Sorted by citations

Items 301–360 of 360

Regulation of Trail Receptor Expression in Human Melanoma
Hersey, P., Zhang, S. Y., & Zhang, X. D. (2005) · Humana Press eBooks · doi:10.1385/1-59259-851-x:175 · Cited by 3
Defective Apoptosis Signaling in Cancer
Johnson, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_1 · Cited by 2
Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer
Wagner, J., Kline, C. L. B., & El‐Deiry, W. S. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56805-8_1 · Cited by 2
Self-citation
Regulation of Death Receptors by Synthetic Retinoids
Sun, S. (2005) · Humana Press eBooks · doi:10.1385/1-59259-851-x:189 · Cited by 2
Therapeutic Modulation of Apoptosis in Cancer Therapy
Fulda, S., & Debatin, K. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch33 · Cited by 2
Death Receptor Pathways As Targets for Anticancer Therapy
Fulda, S., & Debatin, K. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_3 · Cited by 2
p53motifDB: integration of genomic information and tumour suppressor p53 binding motifs
Baniulyte, G., Hicks, S. M., & Sammons, M. A. (2025) · Database · doi:10.1093/database/baaf053 · Cited by 1
Silencing Ubiquitin-Specific Peptidase 10 Alleviates Persistent Corneal Epithelial Defect in Mice
Banerjee, A., Shaik, M. A., Tilstra-Smith, C., Castro, N., Reynoso-García, J., Zuber, M. E., & Bernstein, A. M. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.10.006 · Cited by 1
Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop
Bonavida, B. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_9 · Cited by 1
Cancer Gene Therapy with the p53 Tumor Suppressor Gene
Meng, R. D., & El‐Deiry, W. S. (2002) · Elsevier eBooks · doi:10.1016/b978-012437551-2/50019-7 · Cited by 1
Self-citation
Mortalin-p53 Interaction as a Target for Liver Cancer Therapy
Lü, W., Lee, N. P. Y., Wadhwa, R., & Luk, J. M. (2012) · Springer eBooks · doi:10.1007/978-94-007-3027-4_17 · Cited by 1
Resistance to Apoptosis in Cancer Therapy
McConkey, D. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-851-x:043 · Cited by 1
Transcription factor AP-2 in relation to personality and antidepressant drugs.
Berggård, C. (2004) · Uppsala University Publications (Uppsala University) · Cited by 1
suppressor genes as candidate dosage-dependent tumor TRAIL-R2 and TRAIL-R1 Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma:
Dyer, M. J. S., Martinez-Climent, J. A., Esteller, M., Staudt, L. M., Fernández-Luna, J. L., Rosenwald, A., Climent, J., Martínez, J. I. P., Schilhabel, M. B., Karran, E. L., et al. (2011) · Cited by 1
TRIM22/Staf50 - a novel target gene of the tumor suppressor p53
Obad, S. (2007) · Lund University Publications (Lund University) · Cited by 1
Role of p53 in Regulation of Death Receptors
Takimoto, R. (2005) · Humana Press eBooks · doi:10.1385/1-59259-851-x:201
Self-citation
Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent
Allen, J. E. (2012) · ScholarlyCommons (University of Pennsylvania)
Expression levels of MDM2 and MDMX proteins and their associated effects on P53 in human liposarcomas
Touqan, N. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Strukturelle und funktionelle Charakterisierung von RERE, einem Gen mit möglicher Relevanz bei der Tumorentstehung
Wärner, T. M. (2001) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-1529
Expression and function of the small immune adaptor protein SAP
Nagy, N. (2006) · Figshare
Apoptosis in Cancer Biology and Cancer Therapeutics
Fulda, S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-381-7_26
Harnessing Death Receptor Signaling for Cancer Treatment
Fulda, S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_11
The role of p53 in death receptor-mediated apoptosis of testicular germ cells in response to mono-(2-ethylhexyl) phthalate treatment
Chandrasekaran, Y. (2005) · Texas ScholarWorks (Texas Digital Library)
Mecanismos de indução de apoptose pela presença de danos ao DNA: um estudo sobre o papel de p53 na resistência de células de glioma a agentes quimioterápicos.
Batista, L. F. Z. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2008.tde-22092008-170922
p90 and UHRF1, Two Novel Regulators of the p53 Signaling Pathway
Dai, C. (2014) · doi:10.7916/d8sq8xcj
THE ATTENUATION OF THE P53 RESPONSE TO DNA DAMAGE IN RODENT LIVER PRENEOPLASTIC ENZYME- ALTERED FOCI
Finnberg, N. K. (2003) · Figshare
Modeling p53 transcriptional regulation
Riley, T. (2008) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t31836rn
MECHANISMS OF ANTICANCER DRUG ACTION Chapter II
Wesselborg, S., & Lauber, K. (2005)
Study of novel dual topoisomerase poisons as potential anti-cancer drugs.
Lewis, L. J. (2005) · Surrey Research Insight Open Access (The University of Surrey)
Mechanism of Wogonin-mediated sensitization of HTLV-1-associated ATL cells to TRAIL-induced apoptosis
Ding, J. (2011) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00012242
p53 and Its Targets
Takimoto, R., & El‐Deiry, W. S. (2002) · Elsevier eBooks · doi:10.1016/b978-012476249-7/50005-9
Self-citation
ID4 Acts as a Tumor Suppressor via p53: Mechanistic Insight
Morton, & Derrick, J. P. (2016) · Atlanta University Center Robert W. Woodruff Library (Atlanta University Center Robert W. Woodruff Library)
Identification and regulation of p53 target genes in primary human epidermal keratinocytes
Schavolt, K. L. (2006)
Rottlerin Induces Apoptosis via Death Receptor5 (DR5) Up-Regulation through CHOP-Dependent and PKC d-Independent Mechanism in Human Malignant Tumor Cells
Lim, J. H., Park, J., Choi, K. S., Park, Y. B., & Kwon, T. K. (2008) · Proceedings of the Korean Society of Life Science Conference
Molecules in Signal Pathways
Pan, S., & Zhang, W. (2021) · Springer eBooks · doi:10.1007/978-981-16-1037-0_11
Modulation of TRAIL Signaling for Cancer Therapy
Fulda, S., & Debatin, K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_28
Apoptose
Eichhorst, S. T., & Krammer, P. H. (2003) · Springer eBooks · doi:10.1007/978-3-662-07588-3_7
p53 activity during adenovirus infection
Savelyeva, I. V. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-366
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7056
The MDM2 oncoprotein antagonizes Poly(ADP-ribosyl)ation
Giansanti, C. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9741
Supplementary Tables 1-2 from p53 Is Preferentially Recruited to the Promoters of Growth Arrest Genes p21 and GADD45 during Replicative Senescence of Normal Human Fibroblasts
Jackson, J. G., & Pereira‐Smith, O. M. (2023) · doi:10.1158/0008-5472.22365284
Data from Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
Kandasamy, K., & Kraft, A. S. (2023) · doi:10.1158/1535-7163.c.6532250
Data from Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
Zhou, J., Lu, G.-D., Ong, C.-S., Ong, C. N., & Shen, H. (2023) · doi:10.1158/1535-7163.c.6531960
Data from Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
Duiker, E. W., de Vries, E. G. E., Mahalingam, D., Meersma, G. J., Ek, W. B., Hollema, H., Hooge, M. N. L., van Dam, G. M., Cool, R. H., Quax, W. J., et al. (2023) · doi:10.1158/1078-0432.c.6517572
Pengaruh Ekstrak Daun Sirsak terhadap Ekpresi Gen P53 Sel Kanker Payudara T47D
Rangkuti, A. G., Arisanty, D., & Lestari, Y. (2023) · Jurnal Ilmu Kesehatan Indonesia · doi:10.25077/jikesi.v4i2.561
Tumour-selective apoptosis : identification of NMHCIIa as novel death receptor interactor regulating the response to TRAIL
Schulz, C. (2012) · theses.fr (ABES) · doi:10.70675/b5d0692czcd20z498dz885bz5e10f5af055c
Regulation of Death Receptors
Kontny, U., & Kovar, H. (2005) · Humana Press eBooks · doi:10.1385/1-59259-851-x:163
Novel insights into skyrin action in cancer cells
BARČÁKOVÁ, I., Jendželovská, Z., Blašková, G., Jendželovský, R., & Fedoročko, P. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112008
Rôle de la protéine multifonctionnelle E4F1 et de la voie p53 dans l’homéostasie cutanées
Goguet-Rubio, P. (2013) · theses.fr (ABES) · doi:10.70675/cf006e65z80d3z43f4za521z25580e174bc9
Role of α5β1 integrin/p53 pathway in the resistance of glioma and colon cancer to therapy
Janoušková, H. (2013) · theses.fr (ABES) · doi:10.70675/aea5c2d4z4dffz49cbzab19zef13aac15ac8
Polymorphisms in G-quadruplex regions of the TP53 tumour suppressor gene : Impact on cancer susceptibility and expression of p53 N-terminal isoforms
Sagne, C. (2013) · theses.fr (ABES) · doi:10.70675/ebec5c03z0894z47e9zb462z73d7570ffb65
Etude de la voie d’action intracrine et nucléaire du Fibroblast Growth Factor 1 dans des cellules de type neuronal
Pirou, C. (2016) · theses.fr (ABES) · doi:10.70675/2461ba31z9b9bz4988zabf3z6ffec68d0176
Régulation de l’apoptose dépendante de p53 par le FGF1 intracellulaire : caractérisation des mécanismes d’action
Delmas, E. (2014) · theses.fr (ABES) · doi:10.70675/4d100f0fz18d9z40fbz9787zfc2c1c84028e
Etude du rôle des fibroblastes associés au mélanome dans la modulation de la réponse immune anti-tumorale : influence de la sécrétion de métalloprotéinases matricielles sur la lyse tumorale dépendante des cellules NK et de l’hypoxie sur leur potentiel immunosuppresseur
Ziani, L. (2017) · theses.fr (ABES) · doi:10.70675/a0f25460zb6f0z4657z9194zefca731af42c
c-FLIP as a potent anticancer target : Enhancement of cancer cell apoptosis by compounds identified through virtual screening
Yaacoub, K. (2017) · theses.fr (ABES) · doi:10.70675/c49812bdz7b0az4a95zb5f2z15bd5d386997
Implication de la protéine suppresseur de tumeurs p53 dans la mort cellulaire induite par les lymphocytes T cytotoxiques et les cellules NK : rôle dans la régulation de l’apoptose dépendante du granzyme B
Safta, T. B. (2017) · theses.fr (ABES) · doi:10.70675/42749168zc79fz4340zbd16z7ee117cd9612
Effet de l’inactivation du gène suppresseur de tumeur p53 et de sa réactivation pharmacologique sur la réponse cytotoxique anti-tumorale
Chollat-Namy, M. (2020) · theses.fr (ABES) · doi:10.70675/3981c82bzf3baz4b17zaa7eza762575e0b9d
Use of innovative 3D cellular models to study the impact of intra-tumor heterogeneity in treatment resistance in childhood cancer : proof of concept in H3K27M-diffuse midline glioma and rhabdomyosarcoma
Huchedé, P. (2023) · theses.fr (ABES) · doi:10.70675/82dfb9c9z1a39z4d59z97a2z4db431a7f1b2
Dual Pathways of UBE4B Inhibit Apoptosis in p53-Positive Tumor Cells via CCAR2 Degradation
Jin, B., Qu, J., Xu, P., Zhao, B., & Jiao, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083682
Recent advances in the understanding of TP53 in haematological malignancies
Ng, J. Y., & Talaulikar, D. (2026) · Pathology · doi:10.1016/j.pathol.2026.03.014

Authors: Takimoto, R., & El-Deiry, W. S.
Affiliations: Howard Hughes Medical Institute (US)
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2000-03-30
Volume: 19
Issue: 14
Pages: 1735-1743
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1203489
OpenAlex: W2053301688
Cited by: 360
References: 39
Citations by year: 2026: 3 · 2025: 6 · 2024: 3 · 2023: 12 · 2022: 5 · 2021: 6 · 2020: 11 · 2019: 10 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 12 · 2013: 8 · 2012: 18
FWCI: 7.78
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Japan Health Sciences Foundation
National Cancer Institute (P01CA075138, P01 CA75138-01)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: p53, DR5, TRAIL, p53 target genes, intronic enhancer, transcriptional activation, doxorubicin, p53 stabilization, apoptosis, E6 oncoprotein
MeSH terms: Binding Sites, DNA, DNA Damage, Doxorubicin, Humans, Introns, Oncogene Proteins, Viral, Promoter Regions, Genetic, Tumor Cells, Cultured, Transcriptional Activation, Gene Expression, Tumor Suppressor Protein p53, Mutagenesis, Apoptosis, Genes, Reporter, Receptors, Tumor Necrosis Factor, Receptors, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks